Edwards Lifesciences Corporation
EWHealthcareNASDAQMedical Devices
Scan Results
Daily timeframePart of the healthcare sector, Edwards Lifesciences Corporation (EW) is listed under Medical Devices. The $51.29B market capitalization puts EW squarely in large-cap range for its industry. It offers transcatheter heart valve replacement products for minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL and EVOQUE brands.
Market Cap
$51.29B
Beta
0.86
P/E (TTM)
52.09
P/E (Fwd)
26.40
EPS (TTM)
$1.71
EPS (Fwd)
$3.37
ROE
9.2%
ROA
8.4%
Cash
$4.25B
Total Debt
$704.4M
Free CF
$1.23B
52W Change
17.0%
Annual Financials
Cash vs Debt
Where EW stands vs its 150-day and 200-day moving averages
As of the October 19, 2026 close, EW finished 0.72% above its 150-day moving average ($85.98) and 1.71% above its 200-day moving average ($85.14). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is EW overbought or oversold?
At the October 19, 2026 close, EW's RSI(14) was 49.3, in neutral territory (between 30 and 70). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
Edwards Lifesciences Corporation holds $4.25B in cash against $704.4M in total debt, giving it a net cash position. This means the company could theoretically pay off all its debt and still have cash remaining. The company generates $1.23B in free cash flow annually, which funds everything from R&D to shareholder returns without needing external financing. ROE of 9.2% points to decent capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. An ROA of 8.4% suggests reasonable efficiency in deploying the company's asset base. Revenue has grown from $4.46B (2022) to $6.07B (2025), reflecting a 36% increase over the period.
With cash comfortably exceeding debt, EW has financial flexibility that may help navigate uncertain periods. At over 50x earnings, EW carries valuation risk — any slowdown in growth expectations could lead to meaningful price adjustments. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing EW.